# Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia

> **NCT05081349** · PHASE4 · COMPLETED · sponsor: **Assiut University** · enrollment: 91 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine
- **DRUG:** Hydroxycarbamide 500 Mg Oral Capsule
- **DRUG:** L-Carnitine, 250 Mg Oral Capsule

## Key facts

- **NCT ID:** NCT05081349
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2020-06-10
- **Final completion:** 2021-07-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05081349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05081349, "Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05081349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*